This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SLGC Standard BioTools (SLGC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Standard BioTools Stock (NASDAQ:SLGC) 30 days 90 days 365 days Advanced Chart Get Standard BioTools alerts:Sign Up Key Stats Today's Range$1.93▼$2.3150-Day Range$2.10▼$2.8352-Week Range$1.73▼$3.79Volume33.91 million shsAverage Volume10.83 million shsMarket Capitalization$394.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado. Read More Receive SLGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLGC Stock News HeadlinesIllumina to Buy SomaLogic for Up to $425 Mln -- UpdateJune 23, 2025 | marketwatch.comStandard BioTools jumps on sale of SomaLogic to IlluminaJune 23, 2025 | msn.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 28 at 2:00 AM | Investors Alley (Ad)Standard BioTools cut to Neutral at KeyBanc on guidanceFebruary 27, 2025 | msn.comStandard BioTools announces publication on study using SomaScan PlatformJanuary 8, 2025 | markets.businessinsider.comStandard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature MedicineJanuary 8, 2025 | markets.businessinsider.comStandard BioTools Inc. Reports Q3 2024 Financial PerformanceOctober 31, 2024 | markets.businessinsider.comStandard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K PlatformSeptember 24, 2024 | markets.businessinsider.comSee More Headlines SLGC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Standard BioTools own? Based on aggregate information from My MarketBeat watchlists, some other companies that Standard BioTools investors own include Digital Turbine (APPS), CrowdStrike (CRWD), SoFi Technologies (SOFI), Vuzix (VUZI) and Okta (OKTA). Company Calendar Today8/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:SLGC CIK1837412 Webii.cmlifesciencesspac.com Phone303-625-9000FaxN/AEmployees451Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.16 million Net Margins-159.54% Pretax Margin-159.08% Return on Equity-24.72% Return on Assets-21.62% Debt Debt-to-Equity RatioN/A Current Ratio17.79 Quick Ratio17.29 Sales & Book Value Annual Sales$97.67 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.70Miscellaneous Outstanding Shares188,070,000Free Float160,049,000Market Cap$394.95 million OptionableOptionable Beta1.64 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:SLGC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.